Validation of Diagnostic Codes for Subtrochanteric, Diaphyseal, and Atypical Femoral Fractures Using Administrative Claims Data

Journal of Clinical Densitometry

Volumn 15, Issue 1, 2012, Pages 92-102

  Narongroeknawin, Pongthorn ^a   Patkar, Nivedita M ^a   Shakoory, Bita ^b   Jain, Archana ^a   Curtis, Jeffrey R ^a   Delzell, Elizabeth ^c   Lander, Philip H ^d   Lopez Ben, Robert R ^d   Pitt, Michael J ^d   Safford, Monika M ^e   Volgas, David A ^f   Saag, Kenneth G ^a  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d University of Alabama at Birmingham   (United States)

^e University of Alabama at Birmingham   (United States)

^f University of Missouri   (United States)

Author keywords

Administrative claims data; Atypical femoral fracture; Diaphyseal femoral fracture; ICD 9 diagnostic code; Subtrochanteric femoral fracture

Indexed keywords

ADOLESCENT; ADULT; AGED; ALGORITHM; ARTICLE; DIAGNOSTIC ACCURACY; DIAPHYSEAL FEMUR FRACTURE; FEMALE; FEMUR FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INSTRUMENT VALIDATION; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALABAMA; ALGORITHMS; DATABASES, FACTUAL; DIAPHYSES; FEMALE; FEMORAL FRACTURES; HIP FRACTURES; HUMANS; INSURANCE CLAIM REPORTING; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MIDDLE AGED;

EID: 84856322451     PISSN: 10946950     EISSN: 15590747     Source Type: Journal    
DOI: 10.1016/j.jocd.2011.09.001     Document Type: Article

References (36)

1. National Osteoporosis Foundation. The clinician's guide to prevention and treatment of osteoporosis. Available at: Accessed January 31, 2011. http://www.nof.org/sites/default/files/pdfs/NOF_ClinicianGuide2009_v7.pdf.
2. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535-1541.
3. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. NEngl J Med 2007, 356:1809-1822.
4. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296:2927-2938.
5. Black D.M., Thompson D.E., Bauer D.C., et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000, 85:4118-4124.
6. Bone H.G., Hosking D., Devogelaer J.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189-1199.
7. Chesnut I.C., Skag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19:1241-1249.
8. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280:2077-2082.
9. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1344-1352.
10. McClung M.R., Geusens P., Miller P.D., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001, 344:333-340.
11. Pols H.A., Felsenberg D., Hanley D.A., et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999, 9:461-468.
12. Reginster J., Minne H.W., Sorensen O.H., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11:83-91.
13. Drake M.T., Clarke B.L., Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008, 83:1032-1045.
14. Ing-Lorenzini K., Desmeules J., Plachta O., et al. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 2009, 32:775-785.
15. Kwek E.B., Goh S.K., Koh J.S., et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury 2008, 39:224-231.
16. Lee P., Seibel M.J. More on atypical fractures of the femoral diaphysis. N Engl J Med 2008, 359:316-317. author reply 317-318.
17. Lenart B.A., Lorich D.G., Lane J.M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008, 358:1304-1306.
18. Lenart B.A., Neviaser A.S., Lyman S., et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case-control study. Osteoporos Int 2009, 20:1353-1362.
19. Napoli N., Novack D., Armamento-Villareal R. Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies. Osteoporos Int 2010, 21:705-708.
20. Neviaser A.S., Lane J.M., Lenart B.A., et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008, 22:346-350.
21. Sayed-Noor A.S., Sjoden G.O. Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res 2009, 467:1921-1926.
22. Schneider J.P. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics 2009, 64:18-23.
23. Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009, 24:1095-1102.
24. Black D.M., Kelly M.P., Genant H.K., et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010, 362:1761-1771.
25. Park-Wyllie L.Y., Mamdani M., Juurlink D.N., et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011, 305:782-789.
26. Schilcher J., Michaëlsson K., Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011, 364:1728-1737.
27. Barrett J.A., Baron J.A., Karagas M.R., Beach M.L. Fracture risk in the U.S. Medicare population. J Clin Epidemiol 1999, 52:243-249.
28. Incidence and costs to Medicare of fractures among Medicare beneficiaries aged > or = 65 years-United States, July 1991-June 1992. MMWR Morb Mortal Wkly Rep 1996, 45:877-883. Centers for Disease Control and Prevention.
29. Curtis J.R., Mudano A.S., Solomon D.H., et al. Identification and validation of vertebral compression fractures using administrative claims data. Med Care 2009, 47:69-72.
30. Silverman S.L., Watts N.B., Delmas P.D., et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007, 18:25-34.
31. Odvina C.V., Zerwekh J.E., Rao D.S., et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294-1301.
32. Ray W.A., Griffin M.R., Fought R.L., Adams M.L. Identification of fractures from computerized Medicare files. J Clin Epidemiol 1992, 45:703-714.
33. Spangler L., Ott S.M., Scholes D. Utility of automated data in identifying femoral shaft and subtrochanteric (diaphyseal) fractures. Osteoporos Int 2011, 22:2523-2527.
34. Shane E., Burr D., Ebeling P.R., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25:2267-2294.
35. Heckbert S.R., Kooperberg C., Safford M.M., et al. Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. Am J Epidemiol 2004, 160:1152-1158.
36. Williams G.R., Jiang J.G., Matchar D.B., Samsa G.P. Incidence and occurrence of total (first-ever and recurrent) stroke. Stroke 1999, 30:2523-2528.